Loading
A phase 3 trial of Durvalumab, Tremelimumab, Carboplatin, Gemcitabine + cisplatin, Gemcitabine and Cisplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) is a phase 3 interventional study registered as NCT02542293 by AstraZeneca, with 953 participants enrolled, started 2015-11-03 and due to reach its primary completion in 2020-09-21. Interventions recorded: Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin and Pemetrexed + carboplatin. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
953 enrolled.
95% CI 8.6 to 15.2; Figures from the ClinicalTrials.gov results section (first posted 2022-05-24), not from a publication · 95% CI 7.8 to 12.6
Source95% CI 10.5 to 27.4; Figures from the ClinicalTrials.gov results section (first posted 2022-05-24), not from a publication · 95% CI 8.6 to 20.5
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Setprimary | Global: Durvalumab + Tremelimumab | 69 | 11.7 months | 0.71 (0.485 to 1.045) | 0.0808 | link |
| Global: SoC Chemotherapy | 60 | 9.1 months | ||||
| OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Setprimary | China: Durvalumab + Tremelimumab | 26 | 15 months | 0.6 (0.322 to 1.109) | - | link |
| China: SoC Chemotherapy | 29 | 11.7 months |
Shares Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON)., Lung cancer: the failed and stopped programmes, and why, Tremelimumab, Gemcitabine + cisplatin and the tag pipeline.
Shares Tremelimumab, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Tremelimumab, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Tremelimumab, Durvalumab, AstraZeneca, Cisplatin and the tag pipeline.
Shares Tremelimumab, Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, Cisplatin and the tag pipeline.